Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

Familial Cancer

Volumn 8, Issue 3, 2009, Pages 173-177

  Hubert, Ayala ^a   Mali, Bela ^a   Hamburger, Tamar ^a   Rottenberg, Yakir ^a   Uziely, Beatrice ^a   Peretz, Tamar ^a   Kadouri, Luna ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

BRCA1 2; Breast cancer; Neo adjuvant chemotherapy; Response

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MASTECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68449097071     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-008-9223-7     Document Type: Article

References (24)

1. JN Marcus P Watson DL Page 1996 Hereditary breast cancer: pathology, prognosis and BRCA1 and BRCA2 gene linkage Cancer 77 697 709 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W (Pubitemid 26055395)
2. U Hamann HP Sinn 2000 Survival and tumor characteristics of German hereditary breast cancer patients Breast Cancer Res Treat 59 185 192 10.1023/A:1006350518190 (Pubitemid 30216142)
3. G Rennert S Bisland-Naggan O Barnett-Griness 2007 Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 115 123 10.1056/NEJMoa070608 (Pubitemid 47057729)
4. WD Foulkes N Wong JS Brunet 1997 Germline mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer Clin Cancer Res 3 2465 2469
5. D Stoppa-Lyonnet Y Ansquer H Dreyfus 2000 Familial invasive breast cancers: worse outcome related to BRCA1 mutations J Clin Oncol 18 4035 4039
6. ME Robson PO Chappuis J Satagopan 2004 A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 R8 R17 10.1186/bcr658
7. D Boyd Y Somoda MG Federici 2000 Clinicopathologic features of BRCA linked and sporadic ovarian cancer J Am Med Assoc 283 2260 2265 10.1001/jama.283.17.2260
8. V [tmp] McGuire AS Whitmore R Norris I Oakley-Girvan 2000 Survival in epithelial ovarian cancer patients with prior breast cancer Am J Epidemiol 152 528 532 10.1093/aje/152.6.528 (Pubitemid 30707478)
9. Y Ben David A Chetrit G Hirsh-Yechezkel 2003 Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 463 466 10.1200/JCO.20.2.463
10. DF Foulkes 2006 BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis Fam Cancer 5 135 142 10.1007/s10689-005-2832-5 (Pubitemid 43824469)
11. SR Lakhani J Jacquemier JP Sloane 1998 Multifactortial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations J Natl Cancer Inst 90 1138 1145 10.1093/jnci/90.15.1138
12. DA Levine MG Federici VE Reuter J Boyd 2002 Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer Gynecol Oncol 85 431 434 10.1006/gyno.2002.6646 (Pubitemid 34651880)
13. WD Foulkes K Metcalfe W Hanna 2003 Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma Cancer 98 8 1569 1577 10.1002/cncr.11688 (Pubitemid 37238611)
14. DO Chappuis J Goffin N Wong C Perret 2002 A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 608 610 10.1136/jmg.39.8.608
15. Delaloge S, Pelissier P, Kloos I et al (2002) BRCA1 linked breast cancer is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. 27th ESMO, Niece, France, Abstract no. 120
16. R Rouzier CM Perou WF Symmans 2005 Breat cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 5678 5685 10.1158/1078-0432.CCR-04-2421 (Pubitemid 41170290)
17. LA Carey EC Dees L Sawyer 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2329 2334 10.1158/1078-0432.CCR-06-1109 (Pubitemid 46698581)
18. C Liedtke C Mazouni KR Hess 2008 Response to neoadjuvant chemotherapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 1275 1281 10.1200/JCO.2007.14.4147
19. Bremer M, Steinmann D, Dork T, Borger J, Rades D, Karstens JH (2001) Bilateral breast carcinoma and local recurrence: prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample. Strahlenther Onkol 177:325-329. German. doi: 10.1007/PL00002414
20. TK [tmp] MacLachlan R Takimor WS El-Deiry 2002 BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets Mol Cell Biol 22 4280 4292 10.1128/MCB.22.12.4280-4292.2002 (Pubitemid 34556596)
21. M Fabbro S Schuechner WW Av BR Henderson 2004 BARD1 regulates BRCA1 apoptosis function by a mechanism involving nuclear retention Exp Cell Res 298 661 673 10.1016/j.yexcr.2004.05.004 (Pubitemid 38950880)
22. MS Greenblatt PO Chappuis JP Bond 2001 TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germline mutations: distinctive spectrum and structural distributions Cancer Res 61 4092 4097
23. RE Buller TA Lallas MS Shahin 2001 The P53 mutation spectrum associated with BRCA1 mutation ovarian cancer Clin Cancer Res 7 831 838
24. L Saal SK Grunberger-Saal C Persson 2008 Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers deficient DSB repair Nat Genet 40 1 102 107 10.1038/ng.2007.39